Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study

What Was Tested

The paper reports a study of Thymosin Alpha-1 in the context of cellulite, published as a randomized controlled trial.

The aim of this prospective, double-blinded pilot trial study was to evaluate the effects of Thymosin alpha 1 use in the early phase on immunomodulation and clinical outcomes in patients with severe acute pancreatitis (SAP).

Who Took Part

According to the abstract, 24 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

A total of 24 patients with SAP were randomized to receive either conventional therapy for SAP or immunomodulatory therapy (TA1 group).

How the Study Was Run

The researchers set it up as a randomized, double-blind and pilot study.

The patients were allocated by chance, so the Thymosin Alpha-1 group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Thymosin Alpha-1, so expectations could not easily colour the readings.

It is described as a pilot, a small early test of whether a larger Thymosin Alpha-1 study would be practical.

The serum level of HLA-DR and CD4/CD8 ratio and other immune parameters were measured on admission, the 8th day and the 28th day.

What Was Measured

The subject headings attached to it are Adjuvants, Immunologic, CD4-CD8 Ratio, HLA-DR Antigens, Immunity, Cellular, Monocytes, Pancreatitis and Pneumonia.

What This Means in Plain Language

The paper is a randomized, double-blind and pilot study of Thymosin Alpha-1 in 24 patients in people with cellulite.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2011 (Inflammation), a journal based in United States.

More context: the Thymosin Alpha-1 compound page, Cellulite research.